Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values.

ABSTRACT:

Background

New clinical genomic assays for lymphoid cancers allow for improved disease stratification and prognostication. At present, clinical implementation has been appropriately limited, owing to a paucity of evidence to support clinical and cost effectiveness. Understanding patients' values for precision oncology under conditions of uncertainty can be used to inform priority-setting decisions.

Objectives

Our objective was to ascertain patients' qualitative preferences and attitudes for prognostic-based genomic testing.

Methods

Individuals who were diagnosed with lymphoid cancer between 2000 and 2018 in British Columbia, Canada, were recruited to participate in one of three focus groups. A maximum variation sampling technique was used to capture a diversity of per

SUBMITTER: Costa S 

PROVIDER: S-EPMC7884583 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature